Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...

Approximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.

In the NEULARK trial, patients with early-stage LRRK2-driven Parkinson's disease will receive Neuron23's NEU-411 or a placebo.

LRRK2 inhibitors may be key to combating parkinson's disease Date: June 10, 2014 Source: University of Alabama at Birmingham Summary: An enzyme closely associated with genetic forms of Parkinson ...

This study shows that Parkinson's disease–associated mutant forms of leucine-rich repeat kinase 2 (LRRK2) impair chaperone-mediated autophagy in neurons, thereby reducing degradation of α ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Mutations in LRRK2 account for up to 10 percent of familial PD cases. In addition, the concentration of this protein is elevated in many cases of sporadic disease, hinting at a broad role in pathology ...

More information: Chen, C. et al, LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons, Molecular Psychiatry (2025). DOI: 10.1038/s41380-025-03030-z Provided ...

About LRRK2’s Role in Parkinson’s Disease and NEU-411. Mutations in the LRRK2 gene are among the most common genetic causes of PD, affecting approximately 2% of people with the disease.

About LRRK2’s Role in Parkinson’s Disease and NEU-411. Mutations in the LRRK2 gene are among the most common genetic causes of PD, affecting approximately 2% of people with the disease.

NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027 SOUTH SAN FRANCISCO ...